Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-602-3 | CAS number: 108-64-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The test item has a low acute toxicity by the oral and dermal route.
In rats, the LD50 value via the oral route is > 5000 mg/kg bw (value derived from Read -across compound 3 -methylbutyl isovalerate). In consideration of the molecular weight of both substances (172.27 and 130.18 g/mol), the corrected LD50 for Ethyl isovalerate is > 3778.66 mg/kg.
In rats, the LD50 value via the dermal route is > 2000 mg/kg bw (value derived from Read -across compound ethyl propionate). In consideration of the molecular weight of both substances (102.13 and 130.18 g/mol), the corrected LD50 for the target substance is >2548mg/kg.
No abnormalities were observed during the studies.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2016-03-16 to 2016-07-06
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- The read across justification is included as an attachment to section 13.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- Crl:CD (SD), SPF
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 8 weeks old
- Weight at study initiation: 176.3-195.3 g
- Fasting period before study:animals were fasted overnight, approximately 16 hours prior to dosing
- Housing:cage in an animal room
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: for four days after three days of quarantine (including health examiniation)
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21.5-24.0 °C (measured), permissible range 19-25 °C
- Humidity (%): 43.5-58-5% (measured) permissible range 30-70 %
- Air changes (per hr): 10-15 clean, fresh, filterd air changes per hour
- Photoperiod (hrs dark / hrs light): 12 hours light/12 hours dark
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 500 mg/mL
- Lot/batch no. (if required): MKBS6944V
MAXIMUM DOSE VOLUME APPLIED: 10 ml/kg
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: due to the low expected toxicity of the test substance a starting dose of 5,000 mg/kg was selected. - Doses:
- Step 1: starting dose of 5,000 mg/kg test substance was administered to one animal
Step 2: two animals were administered the test substance at 5,000 mg/kg, becasue there was no dead animal at 5,000 mg/kg (step 1) - No. of animals per sex per dose:
- Step 1 : 1 animal
Step 2: 2 animals - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration:14 days
- Frequency of observations and weighing: observations for mortality, clinical signs, general conditions at 30 minutes after dosing and at 1,2,4,6 hours after dosing on day 0 and once daily thereafter for 14 days; body weight was recorded prior to dosing on day 0 and on day 1, 3,7, and on day of necropsy, day 14
- Necropsy of survivors performed: yes
- Other examinations performed: no histopathology, since no gross findings were obsereved at necropsy. - Statistics:
- Statistical analysis was not performed. Mean scores and values are determined.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 5 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- All animals at 5,000 mg/kg survived the duration of the study. There were no effects on the mortality. Refer to Table 1.
- Clinical signs:
- other: Mucous stool was observed in one animal at 5,000 mg/kg on Day 1 after dosing and it disappeared on Day 2 after dosing. Therefore, it was considered to be a test substance-related temporary change. Refer to table 2.
- Gross pathology:
- No gross visible evidence of morphological abnormalities was observed in any animal at 5,000 mg/kg.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Based on the result of the acute oral toxicity study in Sprague-dawley rats, the test substance has a LD50 value >5000 mg/kg bw. Therefore, it was not classified according to CLP.
- Executive summary:
The purpose of this study was to assess the potential toxicity of the test substance following a single oral dose administration to female Sprague-Dawley rats and to classify the test substance under GHS classification.
Two dose groups were designed as Steps 1 and 2 at 5,000 mg/kg. Step 1 consisted of one female and Step 2 consisted of two females. All animals were monitored for clinical signs and body weight changes during the 14-day observation period after administration. They were subjected to gross necropsy at the end of the observation period.
There were no deaths of animals at 5,000 mg/kg. Mucous stool was observed in an animal on Day 1 after dosing and it disappeared on Day 2 after dosing. A tendency to suppress body weight gain was observed in animals on Day 1 after dosing. Then, these animals returned to normal on Day 3. No test substance-related effects were observed in necropsy findings in any animal.
Based on the result of the acute oral toxicity study in Sprague-Dawley rats, the test substance was not classified according to the GHS classification and the median lethal dose derived was: LD50 cut off> 5,000 mg/kg b.w.
Reference
Table 1: Summary of Mortality
Step / Dose (mg/kg) |
No. of animals |
Days after dosing |
Mortality |
||||||||||||||
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|||
Step 1/ 5,000 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0/1 |
Step 2/ 5,000 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0/2 |
Table 2: Individual Clinical Signs
Step / Dose (mg/kg) |
Animal ID |
Clinical sign |
Hours (Day 0) after dosing |
||||
0.5 |
1 |
2 |
4 |
6 |
|||
Step 1/ 5,000 |
2101 |
|
- |
- |
- |
- |
- |
Step 2/ 5,000 |
2201 |
|
- |
- |
- |
- |
- |
2202 |
|
- |
- |
- |
- |
- |
Step / Dose (mg/kg) |
Animal ID |
Clinical sign |
Days after dosing |
||||||||||||||
|
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
||
Step 1/ 5,000 |
2101 |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Step 2/ 5,000 |
2201 |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
|
2202 |
Mucous stool |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
-: No observable abnormality
+: Observable abnormality
Table 3. Individual Body Weights
Step/Dose (mg/kg) |
Animal ID |
Days after dosing |
Gain 0 ~ 14 |
||||
0 |
1 |
3 |
7 |
14 |
|||
|
|
|
|
|
|
|
|
Step 1 5,000 |
2101 |
176.3 |
185.9 |
202.0 |
212.9 |
234.9 |
58.6 |
Step 2 5,000 |
2201 |
184.6 |
193.8 |
213.4 |
223.8 |
227.5 |
42.9 |
2202 |
195.3 |
198.9 |
214.1 |
228.6 |
235.5 |
40.2 |
|
|
Mean |
190.0 |
196.4 |
213.8 |
226.2 |
231.5 |
41.6 |
S.D. |
7.6 |
3.6 |
0.5 |
3.4 |
5.7 |
1.9 |
|
N |
2 |
2 |
2 |
2 |
2 |
2 |
Table 4. Individual Body Weights during an Acclimation Period
Animal ID |
Temporary Animal ID |
Receipt |
Group assignment |
2101 |
2002 |
170.9 |
198.0 |
2201 2202 |
2001 |
174.3 |
192.5 |
2004 |
180.4 |
204.4 |
|
2003 |
183.9 |
211.3 |
|
|
Mean |
177.4 |
201.6 |
S.D. |
5.9 |
8.1 |
|
N |
4 |
4 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 3 778.66 mg/kg bw
- Quality of whole database:
- The key study has been identified as reliability 1: reliable without restrictions. However, these data have been scored as reliability 2: reliable with restrictions when used for read across to the target test substance. A supporting study, based on the test substance, has been identified as reliability 2, reliable with restrictions as it was a well conducted and reported study but did not follow published protocols.One further supporting study, based on the test substance, has been identified as reliability 4, due to the limited available data.
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- other justification
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Guideline study conducted using a read across substance
- Justification for type of information:
- The read across justification is included as an attachement to Iuclid section 13.
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- other: 3 -methylbutyl isovalerate
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- In an acute dermal toxicity study the LD50 for the source substance 3 -methylbutyl isovalerate was >2000 mg/kg bw in rats. In consideration of the moleculoar weight of both substances (130,18 and 102.13 g/mol), the corrected LD50 for the target substance is > 2549 mg/kg bw. Therefore, using a read-across approach, the target substance was not classified according to CLP classification.
- Executive summary:
The acute dermal toxicity of the target substance was predicted from the source substance (see read-across justification). In an acute dermal toxicity study the LD50 for the source substance was >2000 mg/kg bw in rats. In consideration of the moleculoar weight of both substances (130.18 and 102.13 g/mol), the corrected LD50 value for the target substance is >2549 mg/kg bw. Therefore, using a read-across approach, the target substance was not classified under CLP classification.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 548 mg/kg bw
- Quality of whole database:
- The key source study has been identified as reliability 1: reliable without restrictions. However, these data have been scored as reliability 2: reliable with restrictions when used for read across to the target test substance. The other supporting study, based on the test substance itself, has been identified as reliability 4, due to the limited available data.
Additional information
In the supporting acute oral toxicity studies in rats using the test substance, an LD50 of >5000 mg/kg bw was determined. In the supporting acute dermal toxicity study an LD50 of >5000 mg/kg bw in rabbits was determined.
Justification for classification or non-classification
Based on the available results, the test substance is not classified for acute oral and dermal toxicity according to Regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.